The Serum Institute of India (SII) has applied to the Drug Controller General of India (DCGI) seeking permission to manufacture the Sputnik V Covid-19 vaccine in India. It has also sought permission for test analysis and examination.
It is the third vaccine to be approved by India’s drugs regulator after AstraZeneca’s Covishield – manufactured by SII – and Bharat Biotech’s Covaxin and is currently being manufactured in India by Dr Reddy’s Laboratories.
“The Serum Institute of India (SII) put up an application to the Drugs Controller General of India (DCGI) on Wednesday seeking permission to manufacture the Covid-19 vaccine, Sputnik V, in India,” a source said.
The SII has already told the government that it will be able to manufacture and supply 10 crore Covishield doses in June. Once the permission comes through, the SII will have to conduct clinical trials. If successful, the SII will become the seventh company to manufacture Sputnik V.
